GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Q2 FY27 Consolidated PAT up 14% to INR 512 Million

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 31 Oct 2026, 03:40 PM IST  ·  BSE ID: df1f0ec0-e516-442e-beb7-f4894be75a9c
View Original BSE Filing (PDF)
💡
In Simple Terms
Advanced Enzyme Technologies reported higher profits and revenue for the second quarter and first half of its financial year.
🤖 AI Summary
  • Consolidated Profit After Tax (PAT) for Q2 FY27 increased 14% year-on-year to INR 512 million.
  • Revenue from operations on a consolidated basis grew 16% to INR 2,145 million in Q2 FY27.
  • EBITDA for Q2 FY27 rose 20% year-on-year to INR 721 million, with an EBITDA margin of 34%.
  • Half-yearly PAT for H1 FY27 increased 5% to INR 897 million on revenue of INR 4,062 million.
  • Bio-Processing segment revenue grew 43% year-on-year to INR 365 million in Q2 FY27.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue (Q2 FY27)
2,145 INR Mn.
16%
EBITDA (Q2 FY27)
721 INR Mn.
20%
PAT (Q2 FY27)
512 INR Mn.
14%
Revenue (H1 FY27)
4,062 INR Mn.
10%
PAT (H1 FY27)
897 INR Mn.
5%
Bio-Processing Revenue (Q2 FY27)
365 INR Mn.
43%
🏢 How This Affects the Company
📈
Business Impact
Consolidated revenue grew by 16% year-on-year, driven by strong segmental performances, particularly in Bio-Processing (up 43%) and Animal Nutrition (up 37%). Domestic sales increased by 25% year-on-year, becoming 52% of total revenue, indicating strengthening in the home market.
💰
Financial Impact
Consolidated PAT increased by 14% year-on-year to INR 512 million in Q2 FY27, improving overall profitability. EBITDA margin stood at 34% for Q2 FY27, reflecting a 1 percentage point increase compared to Q2 FY26.
⚙️
Operational Impact
The company is expanding its B2C presence in Human Nutrition in India with the Wellfa brand and investing in R&D and sales teams globally to support product launches and market expansion. Efforts in biocatalysis development for API manufacturers are in various stages, including advanced plant-level trials.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, which showed a 14% year-on-year increase in consolidated PAT to INR 512 million for Q2 FY27.
🔍
Management Signal
Management is focused on expanding its product portfolio, particularly in probiotics, and enhancing business model through R&D and strategic inorganic growth opportunities.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 results — monitor segmental growth, particularly Bio-Processing and Animal Nutrition.
Updates on new product launches under 'Wellfa' brand in Human Nutrition segment.
Progress on biocatalysis plant-level trials with API manufacturers.
LOW RISK Financial results show consistent growth without immediate red flags.
💡 Investor Takeaway
Advanced Enzyme Technologies reported Q2 FY27 consolidated Profit After Tax of INR 512 million, a 14% year-on-year increase. Revenue from operations reached INR 2,145 million, up 16% year-on-year, driven by strong growth in Bio-Processing and Animal Nutrition segments.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 consolidated EBITDA increased by 20% year-on-year to INR 721 million, demonstrating improved operational efficiency.
  • Bio-Processing segment revenue grew significantly by 43% year-on-year to INR 365 million in Q2 FY27, showing strong demand.

⚠️ Concerns

  • Financial costs increased to INR 12 million in Q2 FY27 from INR 7 million in Q2 FY26, representing a 71% year-on-year rise.
  • Human Nutrition segment revenue growth was modest at 6% year-on-year, reaching INR 1,285 million in Q2 FY27.
📅 Company Track Record
Advanced Enzyme Technologies previously reported Q4 FY26 consolidated PAT up 69% YoY to INR 453 million on 22% revenue growth. For Q2 FY27, consolidated net profit rose 11.50% to INR 483.06 million, as per a previous exchange intimation on 2026-10-31.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Advanced Enzyme Technologies' consolidated PAT for Q2 FY27?
Advanced Enzyme Technologies reported a consolidated PAT of INR 512 million for Q2 FY27, marking a 14% year-on-year increase from INR 447 million in Q2 FY26.
What was the revenue from operations for Advanced Enzyme Technologies in Q2 FY27?
Revenue from operations on a consolidated basis for Q2 FY27 was INR 2,145 million, reflecting a 16% year-on-year growth compared to INR 1,845 million in Q2 FY26.
How did Advanced Enzyme Technologies' Bio-Processing segment perform in Q2 FY27?
The Bio-Processing segment revenue grew by 43% year-on-year, reaching INR 365 million in Q2 FY27 from INR 255 million in Q2 FY26.
What were the half-yearly consolidated PAT and revenue for Advanced Enzyme Technologies in H1 FY27?
For H1 FY27, consolidated PAT was INR 897 million, an increase of 5% from H1 FY26. Consolidated revenue from operations for H1 FY27 was INR 4,062 million, up 10% from H1 FY26.
What was Advanced Enzyme Technologies' EBITDA margin in Q2 FY27?
Advanced Enzyme Technologies reported an EBITDA margin of 34% for Q2 FY27, up from 33% in Q2 FY26.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.